World's Best Scientists 2026 revealed!
Christopher E.M. Griffiths

Christopher E.M. Griffiths

D-Index & Metrics

Medicine

D-Index
139
Citations
77122
World Ranking
1749
National Ranking
179

Christopher E.M. Griffiths publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Christopher E.M. Griffiths sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 805 publications — 87th percentile

87% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Christopher E.M. Griffiths D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Christopher E.M. Griffiths sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 139 D-Index — 92nd percentile

92% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2015 - Member of Academia Europaea

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Disease
  • Gene

His primary areas of investigation include Psoriasis, Internal medicine, Dermatology, Immunology and Surgery. Christopher E.M. Griffiths combines subjects such as Quality of life and Disease with his study of Psoriasis. His Internal medicine research incorporates elements of Gastroenterology, Placebo and Endocrinology.

Tretinoin and Negroid is closely connected to Chemotherapy in his research, which is encompassed under the umbrella topic of Dermatology. His studies in Surgery integrate themes in fields like Cohort study, Confidence interval and Ustekinumab. His study in Guselkumab is interdisciplinary in nature, drawing from both Etanercept and Risankizumab.

His most cited work include:

  • Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence (1192 citations)
  • Secukinumab in plaque psoriasis--results of two phase 3 trials. (1146 citations)
  • Pathogenesis and clinical features of psoriasis. (1130 citations)

What are the main themes of his work throughout his whole career to date?

Psoriasis, Internal medicine, Dermatology, Immunology and Pathology are his primary areas of study. His study in Psoriasis focuses on Psoriasis Area and Severity Index in particular. His Psoriasis Area and Severity Index research is multidisciplinary, relying on both Dermatology Life Quality Index, Adverse effect and Severity of illness.

His Internal medicine study integrates concerns from other disciplines, such as Placebo, Endocrinology and Surgery. Christopher E.M. Griffiths works mostly in the field of Endocrinology, limiting it down to topics relating to Human skin and, in certain cases, Retinoic acid, as a part of the same area of interest. Christopher E.M. Griffiths has researched Dermatology in several fields, including Chemotherapy and MEDLINE.

He most often published in these fields:

  • Psoriasis (60.87%)
  • Internal medicine (29.12%)
  • Dermatology (23.45%)

What were the highlights of his more recent work (between 2018-2021)?

  • Psoriasis (60.87%)
  • Internal medicine (29.12%)
  • MEDLINE (8.83%)

In recent papers he was focusing on the following fields of study:

His scientific interests lie mostly in Psoriasis, Internal medicine, MEDLINE, Psoriasis Area and Severity Index and Dermatology. The study incorporates disciplines such as Clinical trial, Intensive care medicine, Disease, Etanercept and Cohort in addition to Psoriasis. He usually deals with Disease and limits it to topics linked to General partnership and Systematic review and Nursing.

His MEDLINE research incorporates themes from Global health, Physiology, Seasonality and Circadian rhythm. His Psoriasis Area and Severity Index study combines topics in areas such as Odds ratio, Dermatology Life Quality Index, Adverse effect and Dosing. In his study, Gastroenterology is strongly linked to Moderate to severe, which falls under the umbrella field of Dermatology.

Between 2018 and 2021, his most popular works were:

  • Clinical applications of machine learning algorithms: beyond the black box. (84 citations)
  • HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis (41 citations)
  • Clinical and genetic differences between pustular psoriasis subtypes (38 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Gene
  • Disease

His primary scientific interests are in Psoriasis, Internal medicine, Psoriasis Area and Severity Index, Cohort and Ustekinumab. His study deals with a combination of Psoriasis and Systemic therapy. Christopher E.M. Griffiths interconnects Dermatology Life Quality Index, Bioinformatics, Transcriptome, Randomized controlled trial and Confidence interval in the investigation of issues within Psoriasis Area and Severity Index.

He combines subjects such as Placebo and Interleukin 17 with his study of Randomized controlled trial. The study incorporates disciplines such as Dermatology, Acrodermatitis, Therapeutic drug monitoring and Cohort study in addition to Cohort. His work focuses on many connections between Ustekinumab and other disciplines, such as Clinical trial, that overlap with his field of interest in Propensity score matching and Number needed to treat.

Best Publications

  • Pathogenesis and clinical features of psoriasis.

    Christopher E. M. Griffiths;Jonathan N. W. N. Barker

  • Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence

    Rosa Parisi;Deborah P.M. Symmons;Christopher E.M. Griffiths;Darren M. Ashcroft

  • Secukinumab in plaque psoriasis--results of two phase 3 trials.

    Richard G. Langley;Boni E. Elewski;Mark Lebwohl;Kristian Reich

  • Psoriasis: epidemiology, clinical features, and quality of life

    R G B Langley;G G Krueger;C E M Griffiths

  • Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

    Andrew Blauvelt;Marjolein de Bruin-Weller;Melinda Gooderham;Jennifer C. Cather

  • Infliximab induction and maintenance therapy for moderate-to-severe psoriasis : a phase III, multicentre, double-blind trial

    Kristian Reich;Frank O Nestle;Kim Papp;Jean-Paul Ortonne

  • British guideline on the management of asthma: A national clinical guideline

    Graham Douglas;Bernard Higgins;Neil Barnes;Anne Boyter

  • Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity

    Lam C. Tsoi;Sarah L. Spain;Sarah L. Spain;Jo Knight;Eva Ellinghaus;Eva Ellinghaus

  • A Genome-Wide Association Study Identifies New Psoriasis Susceptibility Loci and an Interaction Between HLA-C and ERAP1

    Amy Strange;Francesca Capon;Chris C A Spencer

  • Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis

    Christopher E.M. Griffiths;Bruce E. Strober;Peter van de Kerkhof;Vincent Ho

  • Definition of treatment goals for moderate to severe psoriasis: a European consensus

    U. Mrowietz;K. Kragballe;K. Reich;P. Spuls

  • Keratinocytes as initiators of inflammation

    Jonathan N. W. N. Barker;C. E. M. Griffiths;Brian J. Nickoloff;R. S. Mitra

  • European S3-guidelines on the systemic treatment of psoriasis vulgaris

    D Pathirana;AD Ormerod;P Saiag;Catherine Smith

  • Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

    Andrew Blauvelt;Kim A. Papp;Christopher E.M. Griffiths;Bruce Randazzo;Bruce Randazzo

  • A global phase III randomized controlled trial of etanercept in psoriasis : safety, efficacy, and effect of dose reduction

    Kim A. Papp;S. Tyring;M. Lahfa;J. Prinz

  • Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

    Christopher E M Griffiths;Kristian Reich;Mark Lebwohl;Peter van de Kerkhof

  • National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study

    Rosa Parisi;Ireny Y K Iskandar;Evangelos Kontopantelis;Matthias Augustin

  • Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial

    T N Brooklyn;M G S Dunnill;A Shetty;J J Bowden

  • Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

    Kim Papp;Kristian Reich;Craig L. Leonardi;Leon Kircik

  • A genome-wide asociation study identifies new psoriasis susceptibility loci and an interaction betwEn HLA-C and ERAP1

    A. Strange;F. Capon;C. C. A. Spencer;J. Knight

Frequent Co-Authors

Jonathan Barker
Jonathan Barker King's College London
Catherine Smith
Catherine Smith King's College London
John J. Voorhees
John J. Voorhees University of Michigan–Ann Arbor
Helen L. Richards
Helen L. Richards University of Manchester
Dónal G. Fortune
Dónal G. Fortune University of Limerick
Jane Worthington
Jane Worthington University of Manchester
Kim Papp
Kim Papp Probity Medical Research
Ian Kimber
Ian Kimber University of Manchester
Ralf Paus
Ralf Paus University of Miami
Chris J. Main
Chris J. Main Keele University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Aspiring medical professionals benefit from exploring a range of online degrees and career pathways within healthcare. For those interested in the business and management side of medicine, healthcare administration degree programs offer flexible options to build skills in policy, leadership, and operations.

Nurses looking to advance their careers can consider adn to np bridge programs, providing accelerated pathways for experienced RNs to become nurse practitioners. These bridge programs can be especially valuable for those balancing work with further study.

For students interested in preventative care or wellness, earning an online nutrition degree opens doors to roles in dietetics, health education, and public health.

Individuals aiming for leadership roles in hospitals or health systems can pursue accredited mha programs. These Master of Health Administration programs, recognized for their quality standards, are ideal for those seeking to impact healthcare delivery at the organizational level.

Exploring these academic pathways online provides flexibility and a variety of options beyond the traditional MD, catering to evolving career goals in healthcare.

Best Scientists Citing Christopher E.M. Griffiths

Trending Scientists

Recently Published Articles